Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Novel plasmid-mediated CMY variant (CMY-192) conferring ceftazidime-avibactam resistance in multidrug-resistant Escherichia coli

29 Oct 2024

Abstract excerpt

ABSTRACT The rapid rise of multidrug resistance (MDR) among Gram-negative bacteria has accelerated the development of novel therapies. Ceftazidime-avibactam (CZA) is a novel β-lactam/β-lactamase inhibitor recently approved for the treatment of limited infectious diseases. Here, we describe a novel CMY variant, CMY-192, that confers high-level resistance to CZA. This gene was detected in a clinical MDR Escherichia...

Topics

Join the communities discussing this publication.

Antibiotic Resistance in Bacteria
Antibiotics Pharmacokinetics and Efficacy
Pharmaceutical and Antibiotic Environmental Impacts

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 39470201
DOI: 10.1128/aac.00906-24

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Novel plasmid-mediated CMY variant (CMY-192) conferring ceftazidime-avibactam resistance in multidrug-resistant Escherichia coliPMID 39470201Read ↗

High-level ceftazidime-avibactam resistance in <i>Escherichia coli</i> conferred by the novel plasmid-mediated beta-lactamase CMY-185 variantSemantic proximity Read ↗

High-level ceftazidime/avibactam resistance in Escherichia coli conferred by the novel plasmid-mediated β-lactamase CMY-185 variantSemantic proximity Read ↗

A Novel CMY Variant Confers Transferable High-Level Resistance to Ceftazidime-Avibactam in Multidrug-Resistant EscherichiacoliSemantic proximity Read ↗

Structural insights into the molecular mechanism of high-level ceftazidime–avibactam resistance conferred by CMY-185Semantic proximity Read ↗

Epidemiology and Mechanisms of Ceftazidime–Avibactam Resistance in Gram-Negative BacteriaSemantic proximity Read ↗

Molecular mechanisms underlying bacterial resistance to ceftazidime/avibactamSemantic proximity Read ↗

Rapid Emergence of Resistance to Broad-Spectrum Direct Antimicrobial Activity of AvibactamSemantic proximity Read ↗

Ceftazidime–Avibactam Resistance in <i>Escherichia coli</i> Primarily Mediated by <i>bla</i> <sub>NDM-5</sub> with Emergent Ceftazidime–Avibactam/Aztreonam Resistance Linked to <i>bla</i> <sub>CMY-42</sub> VariantsSemantic proximity Read ↗

Acquisition of resistance to ceftazidime-avibactam during infection treatment in Pseudomonas aeruginosa through D179Y mutation in one of two blaKPC-2 gene copies without losing carbapenem resistance.Semantic proximity Read ↗

Selection of mutants with resistance or diminished susceptibility to ceftazidime/avibactam from ESBL- and AmpC-producing EnterobacteriaceaeSemantic proximity Read ↗

Complete Genome Sequence and Characterization of Linezolid-Resistant Enterococcus faecalis Clinical Isolate KUB3006 Carrying a cfr(B)-Transposon on Its Chromosome and optrA-PlasmidSemantic proximity Read ↗

Genetic determinants of intrinsic antibiotic tolerance in <i>Mycobacterium avium</i>Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.